<SEC-DOCUMENT>0001206774-17-002601.txt : 20170823
<SEC-HEADER>0001206774-17-002601.hdr.sgml : 20170823
<ACCEPTANCE-DATETIME>20170823170034
ACCESSION NUMBER:		0001206774-17-002601
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170821
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170823
DATE AS OF CHANGE:		20170823

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CLOROX CO /DE/
		CENTRAL INDEX KEY:			0000021076
		STANDARD INDUSTRIAL CLASSIFICATION:	SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842]
		IRS NUMBER:				310595760
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07151
		FILM NUMBER:		171047622

	BUSINESS ADDRESS:	
		STREET 1:		THE CLOROX COMPANY
		STREET 2:		1221 BROADWAY
		CITY:			OAKLAND
		STATE:			CA
		ZIP:			94612-1888
		BUSINESS PHONE:		5102717000

	MAIL ADDRESS:	
		STREET 1:		P.O. BOX 24305
		CITY:			OAKLAND
		STATE:			CA
		ZIP:			94612-1305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>clorox3302341-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff"><br>
<HR STYLE="MARGIN-TOP: -10PX" SIZE="1" COLOR="Black" >
<HR STYLE="MARGIN-TOP: 5PX" SIZE="1" COLOR="Black">

<P align=center><B><FONT face="Times New Roman" size=5>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=5>SECURITIES AND
EXCHANGE COMMISSION<BR></FONT></B><B><FONT face="Times New Roman" size=2>Washington, D.C. 20549<BR>________________<BR></FONT></B></P>
<P STYLE="text-align: center"><FONT face="Times New Roman" size=5><b>FORM 8-K</b></font></p>
<P align=center><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT><FONT face="Times New Roman" size=2>Pursuant to Section 13 OR
15(d) of the Securities Exchange Act of 1934</FONT> <FONT face="Times New Roman"></FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): August 21, 2017</FONT><FONT face="Times New Roman"></FONT></P>
<P align=center><FONT face="Times New Roman" size=5>THE CLOROX
COMPANY<BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant
as specified in its charter)<BR>________________</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman">Delaware</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman">1-07151</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman">31-0595760</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction of</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(I.R.S. Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>incorporation)</FONT></TD>
    <TD noWrap align=left width="33%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>Identification No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>1221 Broadway, Oakland,
California</FONT></B><B><FONT face="Times New Roman"></FONT></B> <B><FONT face="Times New Roman" size=2>94612-1888<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices) (Zip
code)</FONT><FONT face="Times New Roman"></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(510)
271-7000<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant's
telephone number, including area code)</FONT> <FONT face="Times New Roman"></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Not
applicable<BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or
former address, if changed since last report)</FONT> <FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:</FONT> <FONT face="Times New Roman"></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>[
      ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425 Under the
      Securities Act (17 CFR 230.425)<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>[
      ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12 under the
      Exchange Act (17 CFR 240.14a-12)<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>[
      ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b)
      under the Exchange Act (17 CFR 240.14d-2(b))<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>[
      ]</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="97%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
      under the Exchange Act (17 CFR
240.13e-4(c))</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman" size=2>Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR 240.12b-2).</FONT> <FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Emerging growth
company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="97%"><FONT face="Times New Roman" size=2>If an emerging growth company,
      indicate by check mark if the registrant has elected not to use the
      extended transition period for complying with any new or revised financial
      accounting standards provided pursuant to Section 13(a) of the Exchange
      Act.</FONT></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>&#9744;</FONT></FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=left><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Item 7.01 Regulation FD Disclosure</FONT></FONT></B> <FONT face="Times New Roman"></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>On August 22, 2017, The Company announced that it has sold the Aplicare
skin antisepsis business. The transaction closed on August 21, 2017. The full
text of the press release related to the sale is attached hereto as Exhibit 99.1
and is incorporated herein by reference.</FONT></FONT></P>
<P align=left><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Item 9.01 Financial Statements and Exhibits</FONT></FONT></B></P>
<P align=left><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>(d) Exhibits</FONT></FONT></B> <FONT face="Times New Roman"></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><B>Exhibit</B></FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;<FONT size=3 face="Times New Roman">&nbsp;</FONT>&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=left width="98%"><FONT face="Times New Roman" size=2><B>Description</B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 1%"><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: left; width: 98%"><FONT face="Times New Roman" size=2>Press Release dated August 22, 2017 of The
      Clorox Company</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=center><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>SIGNATURES</FONT></FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</FONT></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="51%"></TD>
    <TD noWrap align=left width="48%" colSpan=3><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>THE CLOROX COMPANY</FONT></FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="51%"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Date: August 23, 2017</FONT></FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>By:</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="46%"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>/s/ Laura
      Stein</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="51%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Executive Vice President
  &#150;</FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="51%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="46%"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>General Counsel and Corporate
      Affairs</FONT></FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=center><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>THE CLOROX COMPANY</FONT></FONT></B> <FONT face="Times New Roman"></FONT></P>
<P align=center><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>FORM 8-K</FONT></FONT></B> <FONT face="Times New Roman"></FONT></P>
<P align=center><B><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>INDEX TO EXHIBITS</FONT></FONT></B><FONT face="Times New Roman"></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" borderColor=#000000 cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: center; width: 1%; padding: 2pt 3pt 2pt 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid"><B><U><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Exhibit</FONT></FONT></U></B></TD>
    <TD NOWRAP STYLE="text-align: left; width: 98%; padding: 2pt 2pt 2pt 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid"><B><U><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Description</FONT></FONT></U></B></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: right; width: 1%; padding: 2pt 3pt 2pt 2pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><A HREF="clorox3302341-ex991.htm#ex991"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>99.1</FONT></FONT></A></TD>
    <TD NOWRAP STYLE="text-align: left; width: 98%; padding: 2pt 2pt 2pt 3pt; border: Black 1pt solid"><A HREF="clorox3302341-ex991.htm#ex991"><FONT face="Times New Roman"><FONT face="Times New Roman" size=2>Press Release dated August 22, 2017 of The
      Clorox Company</FONT></FONT></A></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>clorox3302341-ex991.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 22, 2017 OF THE CLOROX COMPANY
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD NOWRAP WIDTH="50%" STYLE="border-bottom: #808080 1pt solid; text-align: left; vertical-align: middle"><FONT face="Times New Roman" size=2><A NAME="ex991"></A>PRESS RELEASE</FONT></TD>
    <TD style="BORDER-BOTTOM: #808080 1pt solid" noWrap align=right width="50%"><IMG src="clorox3302341-ex991x1x1.jpg" border=0></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman"><FONT face="Times New Roman" size=2><FONT face="Times New Roman" size=3>The Clorox Company Sells
Aplicare to Medline Industries</FONT></FONT></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>OAKLAND, Calif., Aug. 22, 2017
&#150; The Clorox Company (NYSE: CLX) announced today that it has sold the Aplicare
skin antisepsis business<FONT face="Times New Roman"></FONT> to Medline
Industries, the leading privately held manufacturer and distributor of health
care supplies in the U.S. The transaction closed on Aug. 21.</FONT><FONT face="Times New Roman" size=2></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&#147;Selling Aplicare, which was
part of our Professional Products business, was the result of our periodic
strategic assessment of our global portfolio,&#148; said Clorox Chairman and CEO
Benno Dorer. &#147;We are very pleased that, in Medline, we&#146;ve found a buyer that has
strong capabilities and can add significant value to the Aplicare
business.&#148;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Dorer added, &#147;Importantly,
this doesn&#146;t change the strategic focus of our Professional Products business,
which continues to be stopping the spread of infection, with an emphasis on
killing pathogens in the environment.&#148;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>As communicated in the
company&#146;s fiscal year 2017 SEC filings, Clorox had been exploring strategic
alternatives for Aplicare. Clorox's Form 10-K filing<FONT face="Times New Roman" size=2></FONT> on Aug. 15 reported that for fiscal year 2017, which ended June
30, 2017, the Aplicare business had $46 million in net sales, representing
slightly less than 1 percent of total company sales, and insignificant net
earnings.</FONT><FONT face="Times New Roman" size=2></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Clorox will provide an updated
fiscal year 2018 outlook during its first-quarter fiscal year 2018 earnings call
on Nov. 1.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>The Clorox
Company<BR></FONT></B><FONT face="Times New Roman" size=2>The Clorox Company
(NYSE: CLX) is a leading multinational manufacturer and marketer of consumer and
professional products with more than 8,000 employees worldwide and fiscal year
2017 sales of $6 billion. Clorox markets some of the most trusted and recognized
consumer brand names, including its namesake bleach and cleaning products;
Pine-Sol<SUP>&#174;</SUP> cleaners; Liquid Plumr<SUP>&#174;</SUP> clog removers;
Poett<SUP>&#174;</SUP> home care products; Fresh Step<SUP>&#174;</SUP> cat litter;
Glad<SUP>&#174;</SUP> bags, wraps and containers; Kingsford<SUP>&#174;</SUP> charcoal;
Hidden Valley<SUP>&#174;</SUP> dressings and sauces; Brita<SUP>&#174;</SUP>
water-filtration products; Burt&#146;s Bees<SUP>&#174;</SUP> natural personal care
products; and RenewLife<SUP>&#174;</SUP> digestive health products. The company also
markets brands for professional services, including Clorox Healthcare&#174; and
Clorox Commercial Solutions<SUP>&#174;</SUP>. More than 80 percent of the company&#146;s
sales are generated from brands that hold the No. 1 or No. 2 market share
positions in their categories.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Clorox is a signatory of the
United Nations Global Compact, a community of global leaders committed to
sustainability. The company also has been broadly recognized for its corporate
responsibility efforts, most notably receiving a Safer Choice Partner of the
Year Award in 2016 and 2017 from the U.S. Environmental Protection Agency as
well as being named to CR Magazine&#146;s 2017 Best Corporate Citizens list and
included in the 2016 Newsweek Green Rankings. The Clorox Company and its
foundations contributed about $11 million in combined cash grants, product
donations and cause marketing in fiscal year 2017. For more information, visit
TheCloroxCompany.com, including the Good Growth blog, and follow the
company on Twitter at @CloroxCo.</FONT><FONT face="Times New Roman" size=2></FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><FONT face="Times New Roman" size=2><STRONG>Clorox Media Relations<BR>Aileen
      Zerrudo</STRONG><FONT face="Times New Roman" size=2>,
      510-271-3075<BR>aileen.zerrudo@clorox.com</FONT></FONT></TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2><STRONG>Medline Media Relations<BR>Blair Klein,</STRONG><FONT size=3 face="Times New Roman"> </FONT><FONT face="Times New Roman" size=2>847-643-3308<BR><STRONG>bklein@medline.com</STRONG></FONT></FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=2>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%"><B><FONT face="Times New Roman" size=2>Kathryn Caulfield</FONT></B> <FONT face="Times New Roman" size=2>510-271-7209<BR><STRONG>kathryn.caulfield@clorox.com</STRONG></FONT></TD>
    <TD noWrap align=left width="33%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%">&nbsp;</TD>
    <TD noWrap align=left width="33%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%">
      <P><FONT face="Times New Roman" size=2><STRONG>Clorox Investor
      Relations<BR></STRONG>Lisah Burhan 510-271-3269,<FONT size=3 face="Times New Roman"> </FONT><FONT face="Times New Roman" size=2>lisah.burhan@clorox.com<BR>Steve Austenfeld
      510-271-2270,<FONT size=3 face="Times New Roman"> </FONT><FONT face="Times New Roman" size=2>steve.austenfeld@clorox.com</FONT></FONT></FONT></P></TD>
    <TD noWrap align=left width="33%"></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>clorox3302341-ex991x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 clorox3302341-ex991x1x1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O )P# 2(  A$! Q$!_\0
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MZ1^R]X!N(-0MD?0/A/I7Q,_:WU7PIJ,/B;PA9?"WQ4MKI\(!Y5_P46_X+/\
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MZ^(]+\,:M?)HT8!^H]%%% !111_G_/\ G\Z "BC/^?UY]*/\_P"?UH ****
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MHZIX^^.NGZ%\+O#OQ=M-*_:*\9:#;>%_&=Q^RUKMS$UU8?&#Q5#X7M]0\0>
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MH2O  T+%CZ=\??V$?A3^T]^TA\"_CE\<AI_Q*\%? 'P)\5?#GA3]GWQMX/\
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L962,-+,\DTK/*[NW144 %%%% !1110 4444 '^?\_P"?K1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
